Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Horizon Pharma has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for US patent application number 14/705,649 (U.S. publication number 2015-0231264), entitled "Diclofenac Topical Formulation" that covers its US approved product PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%).
Subscribe to our email newsletter
This Notice of Allowance concludes the substantive examination of the patent application and will result in the issuance of a U.S. patent after administrative processes are completed.
The US patent scheduled to issue from this application will expire October 17, 2027. After issuance, Horizon plans to list the U.S. patent in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book.
About PENNSAID 2%
PENNSAID (diclofenac sodium topical solution) 2% w/w is a non-steroidal anti-inflammatory drug (NSAID) indicated for the treatment of pain of osteoarthritis (OA) of the knee(s).
PENNSAID 2% contains diclofenac sodium, an NSAID, and also includes dimethyl sulfoxide (DMSO), a powerful penetrating agent that helps ensure that diclofenac sodium is absorbed through the skin to the site of inflammation and pain.
PENNSAID 2% is an alternative to oral NSAID treatment, reducing systemic exposure to a fraction of that provided by the oral NSAID diclofenac. The only topical NSAID offered with the convenience of a metered-dose pump, PENNSAID 2% is applied in two pumps, twice daily, to the site of OA knee pain.